Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion

ConclusionsOur data strongly support investigation of the chemotherapy-free palbociclib and venetoclax combination as an innovative treatment strategy for post-ibrutinib MCL patients withoutRB1 deletion.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research